📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Thyrocare Infuses Additional USD 475,000 in Tanzania Subsidiary via CCPS
Thyrocare Technologies has invested an additional USD 475,000 (approx. INR 4.33 Crores) into its subsidiary, Thyrocare Laboratories (Tanzania) Limited. This capital infusion was executed through Compulsorily Convertible Irredeemable Preference Shares (CCPS) to support working capital and business operations. The total investment in the Tanzanian venture now reaches approximately INR 10.02 Crores, against a board-approved limit of INR 15 Crores. While the subsidiary is scaling with a turnover of INR 1.84 Crores in 2025, it currently reports a negative net worth of INR 0.32 Crores.
Key Highlights
Additional investment of USD 475,000 (INR 4.33 Crores) via subscription to CCPS.
Total cumulative investment in the Tanzanian subsidiary now stands at INR 10.02 Crores.
Thyrocare Tanzania reported a turnover of INR 1.84 Crores for the year ended December 31, 2025.
The company maintains a 57.25% equity stake and 100% CCPS holding in the joint venture.
Board approval allows for a total investment of up to INR 15 Crores in one or more tranches.
💼 Action for Investors
Investors should monitor the turnaround and scaling of the Tanzanian operations, as the subsidiary currently has a negative net worth. While the investment amount is small relative to Thyrocare's balance sheet, it reflects the company's commitment to international expansion.
Thyrocare Q3 FY26: Revenue Grows 18% YoY; Pathology Up 20% with Record 10,300 Franchisees
Thyrocare reported a strong Q3 FY26 with consolidated revenue growing 18% YoY, led by a 20% surge in the pathology segment. The company processed 49.6 million tests, a 22% increase, and expanded its active franchisee base to a record 10,300 partners. While the core franchisee business grew 12%, the partnership and insurance segments saw robust growth of 39% and 70% respectively. Management also highlighted achieving Six Sigma quality standards and the appointment of new leadership to drive further expansion.
Key Highlights
Consolidated revenue grew 18% YoY, with the core pathology business increasing by 20%.
Total tests processed rose 22% YoY to 49.6 million, serving 4.5 million patients (up 14% YoY).
Active quarterly franchisee base reached an all-time high of 10,300, up from 9,165 in the previous year.
Partnership business revenue jumped 39% YoY, while the pre-policy medical checkup segment grew 70%.
Achieved Six Sigma quality benchmark with 3.2 complaints per million tests, a 43% YoY improvement.
💼 Action for Investors
Investors should monitor the scaling of the partnership business and the path to breakeven for the Tanzania operations. The strong volume growth and record franchisee additions indicate robust market share gains and operational efficiency.
Thyrocare Q3 FY26 Results: Consolidated PAT Jumps 47% YoY to ₹27.9 Cr; Revenue Up 18%
Thyrocare Technologies reported a strong performance for Q3 FY26, with consolidated revenue growing 18% YoY to ₹195.5 crore. The company's profitability saw a significant boost as Reported EBITDA rose 38% YoY to ₹57.6 crore and Profit After Tax (PAT) surged 47% to ₹27.9 crore. Operational metrics remained robust with a 22% increase in tests conducted (49.6 million) and a 14% rise in patient volume. While the radiology segment saw a 7% revenue decline due to strategic exits from non-profitable centers, the core pathology business and partnership segments (up 39%) drove overall growth.
Key Highlights
Consolidated Revenue increased 18% YoY to ₹195.53 crore, driven by 20% growth in standalone pathology.
Reported EBITDA grew 38% YoY to ₹57.64 crore, with margins expanding from 25% to 29%.
Net Profit (PAT) surged 47% YoY to ₹27.91 crore; excluding exceptional items, PAT grew 80% to ₹34.07 crore.
Operational volume reached 49.6 million tests (+22% YoY) and 4.5 million patients (+14% YoY).
Partnership revenue grew by 39% YoY, while the active franchisee base expanded by 12% to approximately 10,300.
💼 Action for Investors
The company demonstrates strong operational leverage and volume-led growth in its core pathology segment. Investors should maintain a positive outlook given the margin expansion and robust partnership growth, while monitoring the impact of the new brand ambassador on retail market share.
Thyrocare Q3 FY26 Results: PAT Surges 47% YoY to ₹27.91 Cr, Revenue Up 18%
Thyrocare Technologies reported a robust Q3 FY26 with consolidated revenue growing 18% YoY to ₹195.53 crore, primarily driven by a 20% growth in the pathology segment. Profit After Tax (PAT) jumped 47% YoY to ₹27.91 crore, while EBITDA increased by 38% YoY to ₹57.64 crore, reflecting strong operational efficiency. The company processed a record 49.6 million tests, marking a 22% YoY volume growth. Additionally, partnership revenue, including PharmEasy, saw a significant 39% YoY increase, further strengthening its market position.
Key Highlights
Consolidated revenue grew 18% YoY to ₹195.53 crore, led by 20% growth in Pathology.
PAT surged 47% YoY to ₹27.91 crore; EBITDA rose 38% YoY to ₹57.64 crore.
Test volumes increased by 22% YoY to 49.6 million tests processed in Q3.
Partnership revenue (including PharmEasy) recorded robust 39% YoY growth.
Achieved Six Sigma quality standards with complaints reduced to 3.2 per million tests.
💼 Action for Investors
Investors should view these results positively as the company demonstrates strong volume growth and margin expansion. The significant growth in partnership revenue and operational benchmarks suggests a sustainable competitive advantage in the diagnostic space.
Thyrocare Q3 FY26 Net Profit Rises 37% YoY to ₹26.15 Cr; Revenue Up 20%
Thyrocare Technologies reported a strong performance for the quarter ended December 31, 2025, with revenue from operations growing 19.6% YoY to ₹182.48 crore. Net profit increased by 36.9% YoY to ₹26.15 crore, even after accounting for an exceptional charge of ₹5.97 crore related to new labor code compliance and capital restructuring. The company successfully executed a 2:1 bonus issue during the quarter, which resulted in the allotment of over 10.61 crore new shares. For the nine-month period, the company has shown robust growth with a net profit of ₹105.23 crore compared to ₹73.96 crore in the previous year.
Key Highlights
Revenue from operations increased 19.6% YoY to ₹182.48 crore from ₹152.55 crore.
Net Profit grew 36.9% YoY to ₹26.15 crore; 9M FY26 profit stands at ₹105.23 crore.
Exceptional item of ₹5.97 crore includes ₹4.01 crore for gratuity adjustments under New Labour Codes.
Successfully completed a 2:1 bonus share allotment on December 1, 2025, increasing paid-up capital to ₹159.16 crore.
Restated Basic EPS for the quarter stands at ₹1.64 compared to ₹1.18 in the year-ago period.
💼 Action for Investors
Investors should take note of the strong double-digit growth in both revenue and profitability, indicating improved operational efficiency. The completion of the bonus issue and the one-time nature of the labor code impact suggest a clean slate for future earnings growth.
Thyrocare Appoints Industry Veteran Rajdeep Panwar as Chief Commercial Officer
Thyrocare Technologies has appointed Mr. Rajdeep Panwar as its Chief Commercial Officer, effective January 05, 2026. Mr. Panwar brings over 21 years of deep industry experience, having held leadership roles at major diagnostic players including Dr. Lal PathLabs, Apollo Diagnostics, and Medanta Labs. His expertise in P&L management and laboratory network expansion is expected to drive the company's commercial growth and market penetration. This appointment strengthens the senior management team as the company looks to scale its diagnostic operations across India.
Key Highlights
Appointment of Mr. Rajdeep Panwar as Chief Commercial Officer effective January 05, 2026
Mr. Panwar brings over 21 years of experience in healthcare and diagnostics industry leadership
Previous experience includes Director at Medanta Labs and roles at Apollo Diagnostics and Dr. Lal PathLabs
Expertise spans P&L management, digital diagnostics, and large-scale laboratory network expansion
The appointment was approved by the Board via circular resolution on January 05, 2026
💼 Action for Investors
Investors should view this as a positive step in strengthening Thyrocare's commercial leadership; monitor for improvements in market share and network expansion in upcoming quarters.
Thyrocare Appoints Rajdeep Panwar as Chief Commercial Officer
Thyrocare Technologies has appointed Mr. Rajdeep Panwar as its Chief Commercial Officer, effective January 05, 2026. Mr. Panwar is a seasoned professional with over 21 years of experience in the diagnostics and healthcare industry, having previously served as Director at Medanta Labs. His career includes leadership roles at major competitors such as Dr. Lal PathLabs and Apollo Diagnostics. This appointment is expected to bolster Thyrocare's commercial strategy and laboratory network expansion across India.
Key Highlights
Appointment of Mr. Rajdeep Panwar as Chief Commercial Officer effective January 05, 2026
Over 21 years of industry experience in healthcare, diagnostics, and laboratory operations
Previous leadership roles at Medanta Labs, Apollo Diagnostics, and Dr. Lal PathLabs
Expertise in P&L management, digital diagnostics, and scaling operations in metro and non-metro markets
💼 Action for Investors
Investors should view this as a positive step towards strengthening the management team with industry-specific expertise. Monitor the company's commercial execution and network expansion progress over the next few quarters.
Thyrocare Appoints Dr. Ramesh Kinha as Chief Operating Officer
Thyrocare Technologies has appointed Dr. Ramesh Kinha as its Chief Operating Officer (COO) effective December 18, 2025. Dr. Kinha is a seasoned professional with over 17 years of experience in the healthcare and diagnostics sector, having previously served as Group Director at Vijaya Diagnostic Centre. His extensive background includes leadership roles at major industry players such as Metropolis Healthcare and SRL Ltd. This appointment is expected to strengthen Thyrocare's operational leadership and strategic execution in the competitive diagnostics market.
Key Highlights
Dr. Ramesh Kinha appointed as Chief Operating Officer effective December 18, 2025
Brings over 17 years of experience across major diagnostic firms including Metropolis, SRL, and Vijaya Diagnostic
Holds an MBBS, MD in Pathology, and senior management certifications from IIM Nagpur and ISB
Expertise spans laboratory services, quality assurance, and organization-wide strategic operations
💼 Action for Investors
Investors should monitor how Dr. Kinha's operational expertise impacts the company's efficiency and service quality. This is a positive leadership addition given his deep industry experience and medical background.
Thyrocare Appoints Dr. Ramesh Kinha as Chief Operating Officer
Thyrocare Technologies has appointed Dr. Ramesh Kinha as its Chief Operating Officer (COO) effective December 18, 2025. Dr. Kinha is a seasoned professional with over 17 years of experience in the diagnostics and healthcare sector, previously serving as Group Director at Vijaya Diagnostic Centre. His extensive background includes leadership roles at major competitors like Metropolis Healthcare and SRL Ltd. This appointment is expected to strengthen Thyrocare's operational leadership and laboratory service quality.
Key Highlights
Dr. Ramesh Kinha appointed as COO and Senior Management Personnel effective December 18, 2025
Brings over 17 years of industry experience from firms like Vijaya Diagnostic, Metropolis, and SRL
Holds an MBBS, MD in Pathology, and management certifications from IIM Nagpur and ISB
Expertise spans laboratory services, operations management, and quality assurance
💼 Action for Investors
Investors should view this as a positive step toward strengthening operational execution; monitor for improvements in service efficiency and margins under the new leadership.
Thyrocare Allots 10.61 Crore Bonus Equity Shares in 2:1 Ratio
Thyrocare Technologies has successfully allotted 10,61,07,794 bonus equity shares to eligible shareholders as of the record date, November 28, 2025. The bonus issue was executed in a 2:1 ratio, meaning shareholders received two new shares for every one share held. This corporate action has increased the company's total paid-up share capital from Rs. 53.05 crore to Rs. 159.16 crore. The total number of outstanding equity shares has tripled to 15,91,61,691 shares.
Key Highlights
Allotment of 10,61,07,794 fully paid-up bonus equity shares of Rs. 10 each
Bonus ratio of 2:1 implemented for all eligible members as of November 28, 2025
Total paid-up share capital increased from 5,30,53,897 to 15,91,61,691 equity shares
Post-bonus paid-up capital value stands at Rs. 159,16,16,910
New shares rank pari-passu in all respects with existing equity shares
💼 Action for Investors
Investors should account for the tripled share count in their portfolios and note that the stock price has adjusted to reflect the 2:1 bonus. No further action is required as the allotment is now complete.